Xiaobin Wu Sells 1,484 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,484 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the transaction, the chief operating officer directly owned 40 shares in the company, valued at $10,774.80. The trade was a 97.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $260.27 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22. The stock’s 50 day moving average is $300.30 and its 200-day moving average is $314.98. The firm has a market capitalization of $28.56 billion, a price-to-earnings ratio of 58.23 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. Sell-side analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

ONC has been the subject of several recent research reports. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the stock from $420.00 to $290.00 in a report on Monday, March 16th. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Barclays upped their price target on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Finally, Guggenheim upped their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Fiera Capital Corp grew its stake in BeOne Medicines by 20.1% in the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock valued at $8,557,000 after purchasing an additional 4,205 shares during the period. BNP Paribas Financial Markets grew its stake in shares of BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after acquiring an additional 97,244 shares during the period. Slow Capital Inc. grew its stake in shares of BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after acquiring an additional 9,280 shares during the period. Generali Investments Management Co LLC bought a new position in shares of BeOne Medicines during the 3rd quarter worth $2,726,000. Finally, Capital International Sarl grew its stake in shares of BeOne Medicines by 2.7% during the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after acquiring an additional 3,956 shares during the period. Institutional investors own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.